JOSÉ LUIS
CABRIADA NUÑO
Chercheur jusqu' 2022
Javier
Pérez Gisbert
Publications dans lesquelles il/elle collabore avec Javier Pérez Gisbert (26)
2024
-
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612
-
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Pharmaceutics, Vol. 16, Núm. 5
2023
-
Development of a Prediction Model for Short-Term Remission of Patients with Crohn’s Disease Treated with Anti-TNF Drugs
International Journal of Molecular Sciences, Vol. 24, Núm. 10
2022
-
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)
Journal of Clinical Medicine
-
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
Biomedicines, Vol. 10, Núm. 3
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
2021
-
Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study
Journal of Clinical Medicine, Vol. 10, Núm. 13
2020
-
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596
2019
-
Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU
Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428
-
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
Therapeutic Advances in Gastroenterology, Vol. 12
2018
-
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 8, pp. 839-851
2017
2014
-
Disease severity in familial cases of IBD
Journal of Crohn's and Colitis, Vol. 8, Núm. 3, pp. 234-239
-
Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database
Journal of Crohn's and Colitis, Vol. 8, Núm. 7, pp. 654-661
-
Risk of colectomy in patients with ulcerative colitis under thiopurine treatment
Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293
2013
-
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome
Journal of Crohn's and Colitis, Vol. 7, Núm. 9, pp. 717-722
-
Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de fármacos antifactor de necrosis tumoral α en la enfermedad inflamatoria intestinal (2013)
Gastroenterologia y Hepatologia, Vol. 36, Núm. 3, pp. 127-146
-
Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients
Inflammatory Bowel Diseases, Vol. 19, Núm. 7, pp. 1404-1410
-
Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era
Alimentary Pharmacology and Therapeutics, Vol. 38, Núm. 7, pp. 752-760